The effectiveness and cost-effectiveness of assistive technology and telecare for independent living in dementia: a randomised controlled trial.


Journal

Age and ageing
ISSN: 1468-2834
Titre abrégé: Age Ageing
Pays: England
ID NLM: 0375655

Informations de publication

Date de publication:
05 05 2021
Historique:
received: 11 05 2020
pubmed: 26 1 2021
medline: 7 8 2021
entrez: 25 1 2021
Statut: ppublish

Résumé

The use of assistive technology and telecare (ATT) has been promoted to manage risks associated with independent living in people with dementia but with little evidence for effectiveness. Participants were randomly assigned to receive an ATT assessment followed by installation of all appropriate ATT devices or limited control of appropriate ATT. The primary outcomes were time to institutionalisation and cost-effectiveness. Key secondary outcomes were number of incidents involving risks to safety, burden and stress in family caregivers and quality of life. Participants were assigned to receive full ATT (248 participants) or the limited control (247 participants). After adjusting for baseline imbalance of activities of daily living score, HR for median pre-institutionalisation survival was 0.84; 95% CI, 0.63 to 1.12; P = 0.20. There were no significant differences between arms in health and social care (mean -£909; 95% CI, -£5,336 to £3,345, P = 0.678) and societal costs (mean -£3,545; 95% CI, -£13,914 to £6,581, P = 0.499). ATT group members had reduced participant-rated quality-adjusted life years (QALYs) at 104 weeks (mean - 0.105; 95% CI, -0.204 to -0.007, P = 0.037) but did not differ in QALYs derived from proxy-reported EQ-5D. Fidelity of the intervention was low in terms of matching ATT assessment, recommendations and installation. This, however, reflects current practice within adult social care in England. Time living independently outside a care home was not significantly longer in participants who received full ATT and ATT was not cost-effective. Participants with full ATT attained fewer QALYs based on participant-reported EQ-5D than controls at 104 weeks.

Identifiants

pubmed: 33492349
pii: 6109729
doi: 10.1093/ageing/afaa284
pmc: PMC8099012
doi:

Banques de données

ISRCTN
['ISRCTN86537017']

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

882-890

Subventions

Organisme : Department of Health
ID : 10/50/02
Pays : United Kingdom

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the British Geriatrics Society. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Références

Dementia (London). 2016 Jul;15(4):681-701
pubmed: 24803646
Qual Life Res. 2005 Aug;14(6):1523-32
pubmed: 16110932
Lancet Neurol. 2019 Jan;18(1):88-106
pubmed: 30497964
Health Econ. 2010 Sep;19(9):1010-28
pubmed: 20665908
J Epidemiol Community Health. 1999 Jan;53(1):46-50
pubmed: 10326053
Age Ageing. 2013 Jul;42(4):501-8
pubmed: 23443509
Int J Geriatr Psychiatry. 2006 Mar;21(3):281-7
pubmed: 16477582
Age Ageing. 1996 Mar;25(2):113-20
pubmed: 8670538
Aging Ment Health. 2019 Aug;23(8):942-951
pubmed: 29634287
Age Ageing. 2010 Jan;39(1):31-8
pubmed: 19934075
Med Care. 1997 Nov;35(11):1095-108
pubmed: 9366889
Nat Rev Neurol. 2019 Jun;15(6):353-359
pubmed: 31073242
Alzheimers Dement (N Y). 2019 Sep 03;5:420-430
pubmed: 31517029
Health Qual Life Outcomes. 2016 Jul 18;14(1):105
pubmed: 27431327
Lancet. 2004 Jun 26;363(9427):2105-15
pubmed: 15220031
BMC Geriatr. 2015 May 13;15:59
pubmed: 25967742
Alzheimers Dement. 2017 Jan;13(1):1-7
pubmed: 27583652
Trials. 2013 Oct 23;14:349
pubmed: 24152600
Gerontologist. 2011 Feb;51(1):76-85
pubmed: 20667944
N Engl J Med. 2013 Apr 4;368(14):1326-34
pubmed: 23550670
Value Health. 2012 Jul-Aug;15(5):708-15
pubmed: 22867780
BMC Geriatr. 2016 Jul 11;16:137
pubmed: 27400744
Stat Methods Med Res. 2002 Feb;11(1):25-48
pubmed: 11923992
Alzheimers Dement. 2018 Jan;14(1):104-114
pubmed: 29161539
Br J Clin Psychol. 1992 Sep;31(3):301-6
pubmed: 1393159
Am J Psychiatry. 1991 Jan;148(1):102-5
pubmed: 1984692
J Telemed Telecare. 2017 May;23(4):460-469
pubmed: 27224997
Health Policy. 1990 Dec;16(3):199-208
pubmed: 10109801
Am J Prev Med. 1994 Mar-Apr;10(2):77-84
pubmed: 8037935
BMJ Open. 2016 Feb 15;6(2):e010208
pubmed: 26880671

Auteurs

Robert Howard (R)

University College London, UK.

Rebecca Gathercole (R)

King's College London, UK.

Rosie Bradley (R)

Medical Research Council Population Health Research Unit, UK.

Emma Harper (E)

Medical Research Council Population Health Research Unit, UK.

Lucy Davis (L)

Medical Research Council Population Health Research Unit, UK.

Lynn Pank (L)

Medical Research Council Population Health Research Unit, UK.

Natalie Lam (N)

Medical Research Council Population Health Research Unit, UK.

Emma Talbot (E)

Norfolk and Suffolk NHS Foundation Trust, UK.

Emma Hooper (E)

Lancashire Care NHS Foundation Trust and University of Manchester, UK.

Rachel Winson (R)

Cambridgeshire and Peterborough NHS Foundation Trust, UK.

Bethany Scutt (B)

King's College London, UK.

Victoria Ordonez Montano (V)

Hertfordshire Community Services NHS Trust, UK.

Samantha Nunn (S)

Cambridgeshire Community Services NHS Trust, UK.

Grace Lavelle (G)

King's College London, UK.

Andrew Bateman (A)

University of Essex, UK.

Peter Bentham (P)

Birmingham and Solihull Mental Health NHS Foundation Trust, UK.

Alistair Burns (A)

University of Manchester, UK.

Barbara Dunk (B)

South London and Maudsley NHS Foundation Trust, UK.

Kirsty Forsyth (K)

Queen Margaret University, UK.

Chris Fox (C)

University of East Anglia, UK.

Fiona Poland (F)

University of East Anglia, UK.

Iracema Leroi (I)

Trinity College Dublin, Ireland.

Stanton Newman (S)

City, University of London, UK.

John O'Brien (J)

University of Cambridge, UK.

Catherine Henderson (C)

London School of Economics and Political Science, UK.

Martin Knapp (M)

London School of Economics and Political Science, UK.

John Woolham (J)

King's College London, UK.

Richard Gray (R)

Medical Research Council Population Health Research Unit, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH